The $1tn+ opportunity for UK biotech
As Big Pharma races to replace billions in patent-expiring revenues, the UK’s “golden triangle” is cementing its role as a global biotech hub - pairing world-class science, clinical infrastructure and a widening funding gap that is reshaping the sector
Autheurs
With public markets grappling with valuation volatility, the UK’s “golden triangle” of innovation – spanning London, Oxford, and Cambridge – continues to produce the next generation of biotech champions. This is underpinned by a “virtuous cycle” of academic excellence, a centralised health system and superior capital efficiency that sustains its position as a premier global hub for drug discovery and clinical development.
Meanwhile, against a looming patent cliff - projected to drive $67 billion in revenue losses by 2029 - large pharmaceutical companies face a growing innovation gap that internal R&D alone cannot fill. With approximately $1.3 trillion in dry powder (EY, January 2025), Big Pharma is therefore increasingly turning to biotech acquisitions, positioning the UK as a key hunting ground for the next wave of life sciences innovation.
But while the UK remains a key acquisition pipeline for global pharma, the more immediate opportunity stems from a sharp contraction in biotech venture fundraising. With investment levels sustained by existing dry powder rather than new capital, a funding vacuum exists - particularly in the UK. This dynamic is likely to pressure valuations, shift bargaining power toward investors, and create an attractive entry point for capital with the potential for strong vintage returns.
The $1 trillion+ imperative
Large pharmaceutical companies are approaching an inflection point. Industry data indicates that the “patent cliff” - the loss of exclusivity following patent expiry, which drives sharp declines in branded drug revenues - is no longer a distant risk but an immediate financial headwind. Global revenue losses from expirations are projected to reach $67 billion in 2029 alone.
This significant revenue gap creates a structural “innovation deficit” that internal R&D alone is unlikely to fill. To address this, large pharmaceutical companies are expected to strengthen their pipelines by acquiring novel therapeutics from biotech companies - effectively turning to external innovation to access potentially transformative discoveries, while offering the prospect of attractive exits for biotech shareholders.
Against this backdrop, the industry holds a staggering $1.3 trillion in “dry powder,” with demand increasingly global. The rise of Chinese biotech - advancing competing therapeutic programs at pace - introduces a credible competitive dynamic, intensifying the race for high-quality assets.
For investors, this sharpens the opportunity rather than undermines it. As public market exits for early-stage platforms have faded and capital has shifted toward precision M&A, the imperative is increasingly on backing novel science underpinned by robust, defensible intellectual property. In this context, the UK’s world-class science, translational research base, and clinical infrastructure continue to provide a differentiated and highly attractive pipeline of assets in an increasingly competitive global landscape.
Science meets infrastructure
The UK’s resilience as a premier global hub for drug discovery and clinical development rests on a 'virtuous cycle' of three distinct pillars: academic excellence, a centralised health system, and a superior capital efficiency.
1. World class scientific output: The foundation of the UK's right to win remains its academic engine. The "golden triangle" is not just a geographic cluster; it is the one of the world’s most productive laboratory for high-growth frontiers like gene editing, antibody drug conjugates, and cell therapies. This consistent scientific output provides critical deal flow that global Big Pharma requires to de-risk its future.
2. Superior capital efficiency: Beyond the science, another potent investment lure is the relative cost-effectiveness of UK biotech vs the US. For institutional investors, the "UK discount" is a feature, not a bug (more on this below). With lower entry valuations and significantly lower employment costs for world-class clinical talent compared US hubs like Boston or San Francisco, capital stretches further in the UK. This efficiency allows biotech's to reach critical clinical milestones on a leaner budget, preserving equity and maximising the "exit premium" when a global giant eventually moves to acquire.
3. The catalyst: infrastructure at the speed of science: While start-ups provide the science and efficiency provides the runway, the UK’s evolving infrastructure acts as an accelerator.
- Clinical specialisation: While often framed through domestic politics, the NHS is also a strategically valuable platform for clinical research, given its scale, longitudinal data, and unified structure. Recent UK life sciences policy has aimed to better leverage NHS data assets.
- Regulatory momentum: The regulatory environment is pivoting toward speed. New government mandates to cut trial setup times to under 150 days are addressing the perennial bottleneck that once drove firms toward Eastern Europe or Asia. For a biotech firm, time is more than money - it is the difference between reaching a Series C or running out of runway.
M&A surge
Mergers and acquisitions involving UK biotech companies gained momentum in 2025, reflecting a global shift where 72% of regulatory approved medications are discovered by biotech companies. A standout development was MSD’s £7.5 billion acquisition of Verona Pharma, one of the largest UK biotech exits in recent years. This transaction signals continued international appetite for UK-originated innovation, even as public markets remain constrained.
Pfizer’s £7.5 billion acquisition of Metsera was another blockbuster deal. Although headquartered in the US, Metsera’s weight-loss pipeline is built on intellectual property spun out of Imperial College London - a reminder that while the US may provide the late-stage funding, the UK often provides the fundamental science.
The UK’s strategic pull was further underscored by Eli Lilly’s $7.8 billion acquisition of Centessa Pharmaceuticals. While Centessa maintains a global footprint, its technological foundation is deeply rooted in the UK ecosystem; it was founded by the life science venture firm Medicxi and built on a portfolio of UK based assets.
Then there was the exit of ViceBio to Sanofi in a deal valued at up to $1.6 billion, including $1.15 billion upfront and up to $450 million in development and regulatory milestones. While ViceBio operates with a global clinical ambition, its formation by Medicxi and roots in academic innovation highlight the UK’s role in building platform-driven biotech companies. The transaction exemplifies how early-stage, UK-linked science can translate into high-value strategic acquisitions by global pharma, particularly when underpinned by differentiated technology platforms and clear pipeline optionality.
Put simply, M&A activity was a clear winner for the biotech sector in 2025, executing a number of high-value exits despite continued weakness in public markets.
With the biotech IPO market effectively dormant for early-stage biotech's, M&A has become the key focus for investors seeking an exit. For the broader ecosystem, these deals provide the vital 'capital recycling' necessary to discover and develop new life-changing medications.
Historically, the UK's Achilles' heel has been the "Valley of Death"- the gap between brilliant seed-stage science and the massive capital required clinical trials. Too often, UK companies were forced to list in New York just to access the depth of capital needed to scale. For example, companies like Autolus Therapeutics and Immunocore bypassed London to list on the Nasdaq. However, we are seeing a shift. The influx of institutional private capital and the reform of pension fund allocations through the Mansion House Accord are beginning to create a pool of domestic "scale-up" capital. This allows firms to stay private longer, until they reach clinical maturity, bypassing the volatility of the public markets. By building value, companies can now remain private until they are prime candidates for a strategic exit to Big Pharma.
Venture market dynamics
Biotech venture capital fundraising has declined sharply from its 2020–2021 peak - falling from roughly $69 billion and over 200 funds to just ~$5 billion across ~20 funds in 2025, marking a 10-year low. In contrast, investment into private biotech companies has remained relatively resilient, stabilising around $37–38 billion annually since 2023, with deal activity also holding broadly steady.
This divergence suggests that firms are continuing to deploy capital from prior fund vintages despite a constrained fundraising environment, effectively drawing down existing dry powder. The result is a tightening capital pipeline, where sustained investment levels are increasingly unsupported by new fund formation, reinforcing the emergence of a structural capital shortfall in the sector.
UK venture activity moderated to £1.8 billion across 58 deals in 2025. However, the most telling metric is not the deal flow itself, but the staggering contraction in venture capital fundraising, amid a challenging broader fundraising environment. While clinical-stage activity persists, the primary pool of domestic VC capital has failed to replenish at the same rate, creating a profound "funding vacuum."
This shortage of biotech venture capital may also reset market dynamics in the coming years. As capital becomes scarcer, valuations may come under pressure, shifting bargaining power toward investors and creating a more favourable entry environment. For those deploying capital over the coming years, this could translate into improved vintage conditions, with lower entry prices potentially supporting stronger exit multiples relative to prior cycles.
Case study
AAVantgarde Bio’s trajectory provides a blueprint for how the UK’s ecosystem acts as a magnet for global clinical development.
For decades, gene therapy has been limited by the physical capacity of the delivery vehicle. The industry standard, Adeno-Associated Virus (AAV), has a strict cargo limit of approximately 4.7 kilobases (kb). This has left hundreds of genetic diseases, including forms of blindness, functionally "undruggable" because their corrective genes are too large to fit in the viral envelope.
AAVantgarde arrived in the UK with a solution: a gene therapy technology that effectively doubles the payload capacity of splitting genes and reassembling them inside the cell. While the foundational science was Italian, the clinical acceleration is British.
The firm’s move to establish a significant UK footprint was driven by the necessity of specialised clinal infrastructure such as Moorfields Eye Hospital.
The financial narrative is equally telling. In late 2025, AAVantgarde secured a $141 million Series B, co-led by Schroders Capital, alongside top tier global biotech VC firms Atlas Venture and Forbion. The syndicate was formed by existing investors Sofinnova Partners and Longwood Fund and new investors included Amgen Ventures, Athos KG, CDP Venture Capital, Columbia IMC, Neva SGR, Sixty Degree Capital, XGen Venture, and Willett Advisors. The Series B closed in Q4 2025, and the proceeds will support AAVantgarde Bio’s study and clinical trial in two severe, inherited retinal disorders: Stargardt disease and retinitis pigmentosa due to Usher syndrome type 1B.
The road ahead
The shifting dynamics of the UK life sciences sector, where recovering public markets are now racing to keep pace with laboratory breakthroughs, represents a window of alpha. This is a sector being revalued as investors eye up the scale of the UK’s innovation imperative.
As the "patent cliff" forces global giants to hunt for high-science assets to protect billions in at-risk annual revenue, the UK’s unique ecosystem has shifted from a mere commercial outpost to a strategic necessity for global capital. The UK may still grapple with its "Achilles' heel" of scale-up capital, but with the Mansion House Accord beginning to mobilise domestic institutional funds, the path from scientific brilliance to global dominance is becoming clearer.
In such an environment, UK biotech will be measured by its ability to discover and develop regulatory approved therapeutics for substantial unmet medical needs, and to partner with larger pharma globally to bring life-changing medications to patients.
Subscribe to our Insights
Visit our preference center, where you can choose which Schroders Insights you would like to receive.
Autheurs
Topics